Cancer Education
focusing on Specialized Topics of Interest

Taught by the Experts

Symposium Co-Chairs

Paul A Bunn Jr MD
Paul A. Bunn, Jr., MD
Distinguished Professor
James Dudley Chair in Lung Cancer Research
Professor, Medical Oncology
University of Colorado Denver
Denver, CO
Fred R. Hirsch, MD, PhD
Fred R. Hirsch, MD, PhD
Professor of Medicine and Pathology
Pia and Fred R. Hirsch Endowed Chair
Associate Director, University of Colorado Cancer Center
CEO, International Association for the Study of Lung Cancer (IASLC)
Denver, CO
H. Jack West, MD
H. Jack West, MD
Medical Director
Thoracic Oncology Program
Swedish Cancer Institute
President and CEO
Global Resource for Advancing Cancer Education (GRACE)
Seattle, WA

Medical Oncology Faculty

Hossein Borghaei, DO
Hossein Borghaei, DO
Chief, Division of Thoracic Medical Oncology
Director, Lung Cancer Risk Assessment
Associate Professor
Department of Hematology/Oncology
Fox Chase Cancer Center
Philadelphia, PA
Walter J. Curran, Jr., MD
Walter J. Curran, Jr., MD
Executive Director, Winship Cancer Institute
Associate Vice President, Cancer,
Woodruff Health Sciences Center
Lawrence W. Davis Professor and Chairman of Radiation Oncology
Group Chairman and Principal Investigator, NRG
Atlanta, GA
Shirish M. Gadgeel, MD
Shirish M. Gadgeel, MD
Director of the Thoracic Oncology Program
Karmanos Cancer Center
Wayne State University
Detroit, MI
Edward B. Garon, MD
Edward B. Garon, MD
Professor of Medicine and
Director, Department of Thoracic Oncology
UCLA Jonsson Cancer Center
Los Angeles, CA
Ronald B. Natale, MD
Ronald B. Natale, MD
Director of the Lung Cancer Clinical Research Program
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA
Suresh Ramalingam, MD
Suresh Ramalingam, MD
Professor of Hematology/Oncology
Deputy Director
Winship Cancer Institute
Director, Lung Cancer Program
Winship Cancer Institute
Assistant Dean for Cancer Research
Co-Leader, Discovery & Developmental
Therapeutics Program
Emory University
Atlanta, GA
Greg Riely, MD
Greg Riely, MD
Medical Oncologist
Thoracic Oncology Service
Vice Chair, Clinical Trials Office
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, NY
Mark A. Socinski, MD
Mark A. Socinski, MD
Executive Medical Director,
Florida Hospital Cancer Institute
Orlando, FL
Heather A. Wakelee, MD
Heather A. Wakelee, MD
Associate Professor of Medicine
Faculty Director, Cancer Clinical Trials Office
Co-Leader, Thoracic Oncology Program
Stanford Cancer Institute
Stanford Comprehensive Cancer Center
Stanford, CA

Oncology Nursing Faculty

Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP
Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP
Clinical Instructor in Nursing
Thoracic Oncology Program
Yale Comprehensive Cancer Center
Yale Schools of Nursing and Medicine
New Haven, CT

Oncology Pharmacist Faculty

Jim M. Koeller, MS
Jim M. Koeller, MS
Professor,
University of Texas at Austin
College of Pharmacy,
Pharmacotherapy Division
Adjoint Professor
University of Texas Health Science Center at San Antonio
School of Medicine, Pharmacotherapy Education & Research
University of Texas Health Science Center at San Antonio
San Antonio, TX
A Multi-Disciplinary CME/CE Cancer Symposium in Los Angeles, CA

For oncologists, hematologists, fellows, nurse practitioners, nurses, pharmacists, & other Healthcare Professionals

Agenda

Back to Top

7:00AM Registration and Full Buffet Breakfast
8:00AM Welcome, Introductions and CME/CE Pre Test
Dr. Bunn
SESSION #1: The Continuing Evolution of IMMUNE THERAPY for Non-Small Cell Lung Cancer and Head & Neck Cancer
Chair: Dr. Bunn
8:10AM Re-evaluating options for 1st-line therapy of NSCLC patients with immune therapy with high-PD-L1 expression levels?
  • Mono-immune therapy
  • Dual Immune therapy
  • Immune therapy plus chemotherapy
  • Immune therapy plus targeted therapy/other combinations
"Rapid-Fire" Questions for the Audience
  • I use immune therapy for some NSCLC patients even after disease progression. YES? NO? UNCERTAIN?
  • Most immune therapies are perceived as being interchangeable? YES? NO? UNCERTAIN?
  • Is PD-L1 testing still necessary for most treatment-naïve NSCLC patients? YES? NO? UNCERTAIN?
Dr. Garon
8:30AM Expert Panel Discussion and Audience Q & A
The expert panel answers the queued-up audience questions submitted via their iPads or their other "smart devices" & from floor microphones, and "Engages in a lively exchange of opinions." Dr. Bunn (Moderator)
8:50AM Mini-Presentation: Re-evaluating options for 1st-line NSCLC therapy using immune therapy for patients with low or no-PD-L1 expression? Dr. Hirsch
9:00AM Salvage options for treating NSCLC patients who have progressed after initial systemic therapy: (immune therapy, chemotherapy, targeted therapy or any combinations). Have the salvage options changed? How and why?
  • What is the role for immune therapy for patients who received chemotherapy in the up-front setting?
  • What are the 2nd-line options using immune therapy?
  • Would the 2nd-line trials of immune therapy versus docetaxel still be positive after removing the high PD-L1 expressers from 1st line? Or otherwise stated, if we are giving the most immuno-sensitive 1st-line patients pembrolizumab are we only left with NSCLC patients who are probable non-responders?
Dr. Wakelee
9:20AM Expert Panel Discussion and Audience Q & A
The expert panel answers the queued-up audience questions submitted via their iPads or their other "smart devices" & from floor microphones, and "Engages in a lively exchange of opinions." Dr. Bunn (Moderator)
9:30AM BREAK
9:50AM Mini-Presentation: When should immune therapy be used in patients with a prior immune-related adverse event (irAE toxicity) that has been resolved? or in patients who presently have an auto-immune disease such as ulcerative colitis, pancreatitis, hypophysitis, etc.? Dr. Garon
10:00AM Mini-Presentation: : Is there a subset of NSCLC patients for whom consideration of using checkpoint inhibition should be a low priority? If yes, how can they be identified? Dr. West
10:10AM Expert Panel Discussion and Audience Q & A
The expert panel answers the queued-up audience questions submitted via their iPads or their other "smart devices" & from floor microphones, and "Engages in a lively exchange of opinions." Dr. Bunn (Moderator)
10:25AM Mini-DEBATE: Immune therapy should be continued indefinitely in NSCLC patients after disease progression, especially after a long, durable response?
  • Yes (Dr. Garon)
  • No (Dr. Wakelee)
Dr. Garon vs. Dr. Wakelee
10:35AM Expert Panel Discussion with Audience Q&A on Issues Related to Discontinuing Immune Therapy
  • Should immune therapy ever be used "indefinitely" for responding NSCLC patients?
  • Should immune therapy for NSCLC patients who have had a long (e.g., 18 months) and durable response to immune therapy, ever be stopped and if so when? What are the considerations?
  • If checkpoint inhibition therapy is stopped for a few months for a responding patient, and then immune therapy is resumed, is it resumed with the same checkpoint inhibitor or a different checkpoint inhibitor? And how long should the temporary halt in treatment be?
  • Are there any NSCLC patients responding to immune therapy for whom we should use immune therapy less frequently? If yes, how can they be identified?
Dr. Garon (Moderator)
10:50AM New Advances Utilizing Radiation Therapy in Combination with Systemic Therapies for NSCLC
  • How should radiation be used in combination with Checkpoint Inhibition for NSCLC patients?
  • What therapy should be following chemo-radiation after Stage III disease?
  • Early-Stage lung cancer
  • Stage IV NSCLC
  • Brain metastases
Dr. Curran
11:05AM Squamous Cell Cancer of the Head & Neck (SCCHN): Immune Therapy for patients with Disease Progression on or after Platinum-BASED THERAPY
Dr. TBD
11:20AM Expert Panel Discussion and Audience Q & A
The expert panel answers the queued-up audience questions submitted via their iPads or their other "smart devices" & from floor microphones, and "Engages in a lively exchange of opinions." Dr. Curran (Moderator)
11:40AM LUNCH "With the Professors" All Physicians
11:40AM LUNCH Nursing Session Dr. Davies
11:40AM LUNCH Pharmacy Session Dr. Koeller
SESSION #2: The Continuing Evolution of CHEMOTHERAPY for Non-Small Cell Lung Cancer
Chair: Dr. Hirsch
12:40PM What are the clinical applications using chemotherapy for nonsquamous NSCLC in the era of immune therapy? In the up-front settings? In the salvage therapy settings?

"Rapid-Fire" Questions for the Audience
  • Chemotherapy remains an important option across all lines of NSCLC therapy for a very large number of NSCLC patients regardless of histology. YES? NO? UNCERTAIN?
  • I understand how to use testing for PD-L1 expression levels for selecting among the various 1st-line and salvage systemic therapy options for squamous NSCLC. YES? NO? UNCERTAIN?
Dr. Ramalingam
12:55PM The new landscape for 1st-line squamous NSCLC: What is optimal therapy and what are the leading considerations for patients with low or no PD-L1 expression? What is optimal up-front therapy for squamous NSCLC patients with high PD-L1 expression? Dr. Socinski
1:10PM Mini-Expert Panel Discussion and Audience Q & A
The expert panel answers the queued-up audience questions submitted via their iPads or their other "smart devices" & from floor microphones, and "Engages in a lively exchange of opinions." Dr. Hirsch (Moderator)
SESSION #3: Molecular Targets, Diagnostic Testing and Targeted and Immune Therapies in NSCLC
Chair: Dr. Ramalingam
1:40PM Current and Emerging NSCLC Molecular Targets: AND What are the clinical applications of current and evolving targeted therapies and standard chemotherapies for these NCSLC targets?
  • Should we routinely test for any of these targets: ROS, BRAF, RET, MET, HER-2, KRAS, CDK4/CDK6?
  • Targeted MAb and TKI therapies, novel chemotherapies, immune therapies
"Rapid-Fire" Questions for the Audience
  • Should all treatment naïve NSCLC patients be tested for PD-L1 expression? YES? NO? UNCERTAIN?
  • Should immune therapies be considered as the third line option after progression on a targeted therapy or standard chemotherapy for a patient with a driver mutation?
Dr. Ramalingam
1:55PM Predicting to use immune therapy: Identifying who will benefit from the several available tests?
  • Is there concordance or discordance among the different PD-L1 tests?
  • Is PD-L1 predictive testing still the gold standard or is there a better way to identify immune-therapy-eligible patients?
  • Should PD-L1 testing be done on everyone who is a candidate for immune therapy?
  • Should mutational load be assessed?
  • What is the role of NGS testing today for immune therapy?
  • Liquid Biopsies: Pros and cons versus Tissue Testing and how to sequence these tests
Dr. Bunn
2:15PM For Squamous NSCLC what are the clinical applications of anti-EGFR targeted and anti-VEGFR & therapies? How do they compare with the other FDA approved options? What about implications for NSCLC maintenance therapy? Dr. Natale
2:30PM Expert Panel Discussion and Audience Q & A
The expert panel answers the queued-up audience questions submitted via their iPads or their other "smart devices" & from floor microphones, and "Engages in a lively exchange of opinions." Dr. Ramalingam (Moderator)
3:00PM BREAK
SESSION #4: The New Landscape for ALK- & EGFR-DIRECTED THERAPIES for NSCLC Patients
Chair: Dr. Riely
3:15PM ALK-Rearrangement NSCLC: 1st Line Therapy Options: Should one of the following four targeted therapies be considered as THE 1st-line standard of care?
  • Crizotinib
  • Ceritinib
  • Alectinib
  • Brigatinib
"Rapid-Fire" Questions for the Audience
  • There is clearly one standard 1st-line anti-EGFR agent for EGFR-positive NSCLC. Yes? No? Unsure?
  • Is it optimal that clinicians use the most effective anti-EGFR or anti-ALK agent in the 1st-line setting or have more options for their patients by using the current 1st-line agent up front? Yes? No? Uncertain?
Dr. Riely
3:35PM Prioritizing therapeutic options post ALK-acquired resistance for 2nd-line and 3rd-line therapies for NSCLC patients. (chemotherapy, vs. further ALK-directed therapy, vs. immune therapy) Dr. West
3:50PM Expert Panel Discussion and Audience Q & A
The expert panel answers the queued-up audience questions submitted via their iPads or their other "smart devices" & from floor microphones, and "Engages in a lively exchange of opinions." Dr. Hirsch (Moderator)
4:05PM EGFR NSCLC: 1st Line Therapy Options (1st, 2nd and 3rd-generation anti-EGFR agents)
  • 1st-line data with a 3rd-generation anti-EGFR vs. using the most effective EGFR agent up front. What does the survival data show?
  • For which patients, if any, are non-anti-EGFR agents considered?
Dr. Borghaei
4:20PM Prioritizing therapeutic options post EGFR-acquired resistance for 2nd-line and 3rd-line therapies for NSCLC patients. Should clinicians do Acquired Resistance (AR) testing post-EGFR-AR, and then prioritize subsequent therapeutic options for 2nd-line and 3rd-line therapies for EGFR-positive NSCLC patients? (chemotherapy, vs. further EGFR-directed therapy, vs. other options) Dr. Gadgeel
4:35PM Expert Panel Discussion and Audience Q & A
The expert panel answers the queued-up audience questions submitted via their iPads or their other "smart devices" & from floor microphones, and "Engages in a lively exchange of opinions."
Dr. Hirsch (Moderator)
4:55PM CME/CE Post Test
Dr. Hirsch
5:00PM Adjourn

Overview

Back to Top

CASE-BASED LEARNING
Sheraton Gateway Los Angeles Airport Hotel, Los Angeles, CA
Saturday, October 21, 2017

This is a one-day CME/CE symposium on the treatment and management of patients with lung cancer. The focus is on community-based medical oncology practices, but all clinicians caring for lung cancer patients are invited, including academic and research-based oncologists and allied healthcare practitioners.

The primary objective is to provide the target audience with the practical knowledge and best clinical practices to help them improve outcome in their lung cancer patients through a focus on personalized medicine with molecular and genomic testing and biomarkers, and an essential integration of the many new and emerging therapies into best practices for their lung cancer patients including immune therapy, new and novel targeted therapies, and novel uses of chemotherapy such as maintenance chemotherapy for squamous NSCLC. The target audience includes both academic and community-based lung cancer oncologists, pathologists, radiologists, surgeons, hematologists, fellows, oncology pharmacists, oncology nurses, Nurse Practitioners, physician assistants and other allied healthcare professionals. The focus is on community-based practices, but all clinicians are targeted, including academic and research-based oncologists and allied healthcare professionals.

On behalf of the world-class faculty of expert lung cancer medical oncologists, an Advanced Nurse Practitioner, and a Professor of Pharmacy, we are very pleased to invite you to attend the forthcoming one-day, multi-disciplinary CME/CE program: The 10th Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer. This is THE lung cancer symposium to attend in 2017. The symposium will present practical information that is relevant to lung cancer practices, presented in case-based learning by lung cancer experts. During 8 hours on a Saturday, it will provide the precise summarized information you need to be totally up-to-date on how to treat your lung cancer patients to improve their outcomes.

Participants will enjoy a highly interactive educational program. Real-life patient cases are used throughout the day addressing the application of new clinical strategies with personalized medicine for lung cancer.

Using iPads or other smartdevices provided at the symposium, participants will make patient management and treatment decisions involving clinical cases presented by the expert lung cancer faculty.

Participants will also use iPads to "answer yes or no" to rapid-fire questions on key topics addressing unmet medical needs; to vote on several lively debates addressing new and emerging clinical strategies; and, to take personal notes on the slides of the presentations. Each participant’s notes along with copies of all data presented throughout the day will be emailed to each participant immediately following the symposium.

During the past year a large amount of new information addressing the unmet medical needs of lung cancer patients has been published. This includes novel therapies and new and emerging standards of care. Strategies involving best clinical practices with personalized medicine are the focus of this symposium. And the timing of this program is designed to provide the participants with the most important clinical and scientific data of the year. This material is the most up-to-date possible on lung cancer.

Now in its 10th consecutive year, this symposium provides a one-day update on the latest developments in the care and management of lung cancer patients. Up to 8.25 hours of CME/CE credit can be earned for participating.

Bring your own Smartphones, Tablets, or Laptops
(iPad, Android, iPhone, etc.): This will enable participants to use their personal "smart devices" during the symposium to ask and answer all questions of the faculty.

 

Educational Need

Back to Top

In 2017, lung cancer remains the leading cause of cancer deaths in the US, and also remains a significant unmet medical need, and, is expected to be a major clinical and scientific challenge for the foreseeable future, but with modest incremental advances. According to the American Cancer Society Facts and Figures there were an estimated 225,500 new cases, and 155,870 deaths from lung cancer this in 2016, almost identical to the prior year’s data. Survival rates for patients with lung cancer vary widely depending upon the stage of the lung malignancy when it is initially diagnosed. The five-year survival rate for Stage I NSCLC is approximately 50 percent. Perhaps more importantly, because most lung cancer are diagnosed at late stages of disease, especially Stages II and mostly IV, the five-year survival rate for Stage IV NSCLC is approximately two percent. Thus, it is clear that there is incredible opportunity for improving outcomes for patients with lung cancer. What is exciting and provides optimism are the increasing advances being made with immune therapy and new-generation targeted therapies, alone and in various combinations, including chemotherapy and existing targeted therapy, and especially for NSCLC patients with the EGFR mutation, the ALK-gene rearrangement, squamous NSCLC, and patients with rare driver mutations.


Target Audience

Back to Top

This activity is designed to meet the educational needs of and help close the quality clinical performance practice gaps of medical oncologists, radiation oncologists, surgical oncologists, pathologists, oncology pharmacists, oncology nurses/Nurse Practitioners and other allied health-care professionals involved in the treatment, care and management of patients with lung cancer and Head & Neck Cancer, including physician assistants, fellows and other HCPs. Lung cancer and Head & Neck cancer are both treated optimally by a multi-disciplinary approach of clinicians and, thus, all of the aforementioned clinician specialties are targeted for invitation to these CME/CE activities for personalized therapies and best clinical practices.

Targeting this audience of clinicians and scientists is intended to help improve the dissemination of the most current and practical educational information required for closing quality clinical performance practice gaps and improving the outcomes of NSCLC and Head & Neck cancer patients through maximized application of personalized medicine and best clinical practices. With the very rapidly increasing number of new targeted and immune therapies, including next-generation anti-VEGF antibodies, new small targeted molecules, and immune checkpoint inhibitors for which most do not yet have validated biomarkers, and key chemotherapies the term, “best practices” takes on increasing significance.


Learning Objectives

Back to Top

Physicians

  1. Understand how to apply the different various approved and emerging immune therapy strategies for NSCLC patients in the treatment naïve and salvage settings.
  2. Compare and contrast the various immune therapy and chemotherapy options in treatment-naïve NSCLC without driver mutations in patients with high, low or no expression of PD-L1.
  3. Evaluate the scenarios for when, if ever, to temporarily discontinue, and when to resume immune therapy in a NSCLC patient that is responding to therapy.
  4. Analyze the new and existing strategies including immune therapy, novel chemotherapy and targeted therapy for patients with squamous NSCLC across all lines of therapy including the treatment-naïve, relapsed and maintenance settings.
  5. Evaluate the large number of open clinical trials offering various combinations of immune and targeted therapies for NSCLC and Head & Neck cancer as possible options for enrolling eligible patients to possibly improve outcome.
  6. Compare and contrast the various sequencing strategies for managing acquired resistance to anti-EGFR and anti-ALK therapy, including when to use the most effective of the three generations of EGFR-directed and ALK-directed TKI therapies “up front” versus saving them for salvage therapy.
  7. Understand when and how to use liquid biopsies versus larger gene panels to help guide serial biopsies when there is insufficient tissue available.
  8. Compare and contrast the various strategies targeting EGFR mutations in NSCLC, including monotherapy versus combination therapy and the impact on therapy related to differences in mutations.
  9. Evaluate the pros and cons of using Stereotactic Ablation Body Radiation (SABR) as an equivalent alternative standard of care to surgery for stage I NSCLC patients.
  10. Understand the pros and cons of prophylactic cranial irradiation in NSCLC considering the advances with TKIs and other systemic therapy.
  11. Compare and contrast the new FDA-approved immune therapies for squamous cell cancer of the Head & Neck (SCCHN).

Nurses

  1. Recall the various immune therapy and chemotherapy options in treatment-naïve NSCLC without driver mutations in patients with high, low or no expression of PD-L1.
  2. List the different various approved and emerging immune therapy strategies for NSCLC patients in the treatment naïve and salvage settings.
  3. Identify the scenarios for when, if ever, to temporarily discontinue, and when to resume immune therapy in a NSCLC patient that is responding to therapy.
  4. Define the new and existing strategies including immune therapy, novel chemotherapy and targeted therapy for patients with squamous NSCLC across all lines of therapy including the treatment-naïve, relapsed and maintenance settings.
  5. List the most important open clinical trials offering various combinations of immune and targeted therapies for NSCLC and Head & Neck cancer as possible options for enrolling eligible patients to possibly improve outcome.
  6. Recall the various sequencing strategies for managing acquired resistance to anti-EGFR and anti-ALK therapy, including when to use the most effective of the three generations of EGFR-directed and ALK-directed TKI therapies “up front” versus saving them for salvage therapy.
  7. Describe when and how to use liquid biopsies versus larger gene panels to help guide serial biopsies when there is insufficient tissue available.
  8. Recall the various strategies targeting EGFR mutations in NSCLC, including monotherapy versus combination therapy and the impact on therapy related to differences in mutations.
  9. List the pros and cons of using Stereotactic Ablation Body Radiation (SABR) as an equivalent alternative standard of care to surgery for stage I NSCLC patients.
  10. Describe the pros and cons of prophylactic cranial irradiation in NSCLC considering the advances with TKIs and other systemic therapy.
  11. Review the new FDA-approved immune therapies for squamous cell cancer of the Head & Neck (SCCHN)

Pharmacists

  1. Recall the various immune therapy and chemotherapy options in treatment-naïve NSCLC without driver mutations in patients with high, low or no expression of PD-L1.
  2. List the different various approved and emerging immune therapy strategies for NSCLC patients in the treatment naïve and salvage settings.
  3. Identify the scenarios for when, if ever, to temporarily discontinue, and when to resume immune therapy in a NSCLC patient that is responding to therapy.
  4. Define the new and existing strategies including immune therapy, novel chemotherapy and targeted therapy for patients with squamous NSCLC across all lines of therapy including the treatment-naïve, relapsed and maintenance settings.
  5. List the most important open clinical trials offering various combinations of immune and targeted therapies for NSCLC and Head & Neck cancer as possible options for enrolling eligible patients to possibly improve outcome.
  6. Recall the various sequencing strategies for managing acquired resistance to anti-EGFR and anti-ALK therapy, including when to use the most effective of the three generations of EGFR-directed and ALK-directed TKI therapies “up front” versus saving them for salvage therapy.
  7. Describe when and how to use liquid biopsies versus larger gene panels to help guide serial biopsies when there is insufficient tissue available.
  8. Recall the various strategies targeting EGFR mutations in NSCLC, including monotherapy versus combination therapy and the impact on therapy related to differences in mutations.
  9. List the pros and cons of using Stereotactic Ablation Body Radiation (SABR) as an equivalent alternative standard of care to surgery for stage I NSCLC patients.
  10. Describe the pros and cons of prophylactic cranial irradiation in NSCLC considering the advances with TKIs and other systemic therapy.
  11. Review the new FDA-approved immune therapies for squamous cell cancer of the Head & Neck (SCCHN)

CME/CE Accreditation and Credit Designation

Back to Top

Physicians

The BioMedical Learning Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The BioMedical Learning Institute designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacists

The BioMedical Learning Institute is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

UAN: 0838-0000-17-003-L01-P
Credits: 8.25 hours (0.825 ceu)
Type of Activity: Knowledge

To receive CE contact hour credit, attendance at the entire activity and the successful completion of the post‐test and evaluation form is required.

Nurses

The BioMedical Learning Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The BioMedical Learning Institute designates this educational activity for 8.25 contact hours.

Accreditation by the American Nurses Credentialing Center's Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

To receive CE contact hour credit, attendance at the entire activity and the successful completion of the post‐test and evaluation form is required.

Other

Physician Assistants: AAPA accepts certificates of attendance for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician Assistants may receive a maximum of 8.25 hours of Category 1 credit for attending this symposium.

Fellows will receive a certificate of attendance that they can submit to their accrediting organizations for continuing education credit.


Location of this Symposium

Back to Top

Sheraton Gateway Los Angeles Airport Hotel
6101 W Century Blvd
Los Angeles, CA 90045
Phone: (310) 642-1111

Hotel Sleeping Rooms

The deadline for the $159/night discounted room rate will expire on Monday, September 27, 2017.

Click here to reserve your room at the discounted rate.


Exhibit Information

Back to Top

There is an opportunity to exhibit at this symposium. Please send an email to exhibits@bmli.com for more information or call 214-269-2014

EXHIBIT FEES:

  • The fee for a 6-foot tabletop display is $1,999.

TERMS FOR EXHIBITORS:

  • Exhibitors who are not registered attendees to the symposium will not have access to the buffet breakfast or the buffet Lunch with the Professors.
  • The Exhibitors will not have access to the scientific sessions unless they are registered for the activity.

Educational Support

Sincere appreciation is extended to companies providing support for this independent educational activity.

Bristol-Myers Squibb
AstraZeneca
Takeda Oncology
Lilly
Novartis
More company support pending
Table of Contents
Educational Partner